

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Robinson, et al.
Serial No.: 10/672,724
Filed: 09/25/03
Entitled: **Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors**

Group No.: 1612
Examiner: Packard

INTERVIEW SUMMARY

EFS Web Filed
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8	
I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being transmitted to the United States Patent and Trademark Office transmitted via the Office electronic filing system in accordance with 37 C.F.R. §1.6(a)(4).	
Dated: <u>June 20, 2008</u>	By: <u>/Joanne Doornbosch/</u> Joanne Doornbosch

Examiner Packard:

The present communication is responsive to the interview conducted May 14, 2008.

The Commissioner is hereby authorized to charge any fees during the entire pendency of this application, including fees due under 37 C.F.R. §§ 1.16 and 1.17 that may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-4302, referencing Attorney Docket No. UCI-12094. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

REMARKS

The present communication is responsive to the interview conducted May 14, 2008. Applicants wish to make the substance of this interview of record. This is provided below.

Record of Interview Substance

Applicants provide herewith the following interview summary to be made of record with respect to the subject application. Applicants thank the Examiner for the helpful interview (hereinafter, Interview). The substance of the Interview was as follows:

Participants: Ben Packard (Examiner), Fred Krass (SPE), and Jason Bond (Attorney)

Date of Interview: May 14, 2008

Interview type: Telephonic

Exhibit shown or demonstration conducted: None

Claims discussed: Independent Claim 28.

Art discussed: Hirsch et al. (The New England Journal of Medicine, 1993, 328(23):1686-1695.

General thrust of the Applicant's principal arguments: The art cited in the Final Office Action does not address Applicants' previous amendment to Claim 28 where the combination of the reverse transcriptase inhibitor and integrase inhibitor has a therapeutic effect on the patient "that is greater than the sum of the effect observed if said transcriptase inhibitor and integrase inhibitor were administered individually." Specifically, the Final Office Action, on page 5, asserts that the combination of the reverse transcriptase (that the patient is resistant to) and another drug (protease inhibitor) would be expected to have "an additive inhibitory effect." Applicants pointed out that they agreed with this conclusion and noted that this provided evidence of the lack of obviousness of the claims since the claims specifically recite more than an additive effect.

General indication of any other pertinent matters discussed: The Examiner and SPE indicated that Examiner Huynh was no longer employed by the Patent Office.

General results or outcome of the Interview: The Examiner and SPE agreed that the claims should either be allowed or a new Office Action should be issued and, as a result, that Applicants did not need to respond to the Final Office Action mailed March 18, 2008. Therefore, there is not a pending action to which the Applicants are to respond.

CONCLUSION

Should the Examiner believe that a telephone interview would aid in the prosecution of this application, the Applicants encourage the Examiner to call the undersigned at 608-218-6900.

Dated: June 20, 2008

/ Jason R. Bond /

Jason R. Bond

Registration No. 45,439

CASIMIR JONES S.C.

440 Science Drive, Suite 203

Madison, WI 53711

608.218.6900